476 related articles for article (PubMed ID: 31002440)
1. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.
Hage C; Hoves S; Strauss L; Bissinger S; Prinz Y; Pöschinger T; Kiessling F; Ries CH
Hepatology; 2019 Oct; 70(4):1280-1297. PubMed ID: 31002440
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
[TBL] [Abstract][Full Text] [Related]
3. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
Yang Y; Sun M; Yao W; Wang F; Li X; Wang W; Li J; Gao Z; Qiu L; You R; Yang C; Ba Q; Wang H
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179631
[TBL] [Abstract][Full Text] [Related]
4. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C
Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703
[TBL] [Abstract][Full Text] [Related]
5. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2.
Li C; Wei S; Xu X; Jiang Y; Xue L; Jiang P; Wang J
Int Immunopharmacol; 2019 Nov; 76():105855. PubMed ID: 31472321
[TBL] [Abstract][Full Text] [Related]
7. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
8. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
9. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
Kohga K; Takehara T; Tatsumi T; Ishida H; Miyagi T; Hosui A; Hayashi N
Hepatology; 2010 Apr; 51(4):1264-73. PubMed ID: 20099300
[TBL] [Abstract][Full Text] [Related]
11. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
12. Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.
Shin S; Kim M; Lee SJ; Park KS; Lee CH
Cancer Genomics Proteomics; 2017; 14(5):349-362. PubMed ID: 28871002
[TBL] [Abstract][Full Text] [Related]
13. Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Won JK; Yu SJ; Hwang CY; Cho SH; Park SM; Kim K; Choi WM; Cho H; Cho EJ; Lee JH; Lee KB; Kim YJ; Suh KS; Jang JJ; Kim CY; Yoon JH; Cho KH
Hepatology; 2017 Sep; 66(3):855-868. PubMed ID: 28439950
[TBL] [Abstract][Full Text] [Related]
14. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
15. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
16. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
17. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells.
Hu J; Wang E; Liu L; Wang Q; Xia D; Bai W; Tie J; Li X; Yuan J; Yang S; Jiang D; Shi J; Sun Y; Wang J; Zhang C; Niu J; Li K; He C; Guo W; Lv Y; Chen H; Yuan X; Yu T; Wang Z; Luo B; Han N; Zhu Y; Yin Z; Fan D; Zhang Z; Yang K; Han G
Invest New Drugs; 2020 Oct; 38(5):1247-1256. PubMed ID: 31832851
[TBL] [Abstract][Full Text] [Related]
19. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.
Liang Q; Kong L; Du Y; Zhu X; Tian J
Exp Mol Med; 2019 Jul; 51(7):1-11. PubMed ID: 31285418
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
Deng M; Li L; Zhao J; Yuan S; Li W
Cancer Chemother Pharmacol; 2018 May; 81(5):853-862. PubMed ID: 29532153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
